Abstract: A polysaccharide derivative having the structure Sacch--O--Z--Ar--CH.dbd.N--Y or ##STR1## where Sacch--O-- represents a polysaccharide molecule; Z is --(CH.sub.2).sub.n -- or ##STR2## Ar is a divalent aromatic group; Y is (a) a monovalent group derived from a water-soluble substituted or unsubstituted aromatic compound containing only one free primary amine group, or (b) a monovalent group derived from a water-soluble substituted or unsubstituted aliphatic or cycloaliphatic compound containing only one primary amine group, or (c) a multivalent group derived from a water-soluble protein containing more than one primary amine group; n is one or greater; and m is zero or greater, is prepared by first modifying the polysaccharide with a reagent to introduce free aromatic aldehyde groups and then reacting with a suitable amine-containing reagent. The siloxane-containing starch derivaties are useful in glass forming size compositions.

Abstract: An antiviral composition for adminisitration to a mammal, in particular, intranasally, for the treatment of the common cold by control of common rhinoviruses. The composition is an inclusion complex of a cyclodextrin, e.g. an .alpha.-, .beta.- or .gamma.-cyclodextrin or derivatives thereof and an antiviral agent.

Abstract: A new inclusion complex of ibuproxam with beta-cyclodextrin is described, which is prepared by adding ibuproxam to a boiling aqueous solution of beta-cyclodextrin, stirring the reaction mixture at the boiling temperature, cooling to a temperature of 0.degree. C. to 5.degree. C. and isolating the title complex.The analgesic, antipyretic and antiinflammatory properties of the inclusion complex of ibuproxam with beta-cyclodextrin are equivalent to those of ibuproxam alone, but owing to its better water-solubility the complex can be more easily formulated into pharmaceutical forms.

Abstract: The media is permethylated hydroxy ether of cyclodextrin and is used in capillary gas chromatographic columns.

Abstract: The present invention relates to novel isomers of PGAs, PGDs, PGEs, PGFs, 6-keto-PGE.sub.1 s, 6-keto-PGF.sub.1 s, PGI.sub.2 s, 6,9.alpha.-nitrilo-PGI.sub.1 s and 6,9.alpha.-methano-PGI.sub.2 s, having a specific steric configuration, which are replaced by an alkyl (C.sub.1 to C.sub.8)-substituted cycloalkyl (C.sub.4 to C.sub.7) group in 1S,S) form, in 1S,R) form or in cis form at the 15-, 16- or 17-position of the PG skeleton, and, alkyl esters thereof, non-toxic salts thereof, non-toxic acid addition salts thereof and cyclodextrin clathrates thereof, possessing more potent PG-like pharmacological activity than other isomers.

Abstract: This invention provides a simple and efficient technique for isolating and purifying alpha-, beta- and especially gamma-cyclodextrins, and also their chemical derivatives. The isolation of different cyclodextrin subforms is based on the use of specially designed macromolecular adsorbents. These adsorbents contain covalently bound ligands which are of suitable size to penetrate the internal cavity of the cyclodextrin molecules and form specific inclusion complexes with cyclodextrins. By means of this invention it is also possible to increase the proportion of any of the cyclodextrin subforms or its chemical derivative by removing the corresponding cyclodextrin subform with a specific sorbent.

Abstract: Cyclodextrin clathrates of carbacyclin analogs of general Formula I ##STR1## wherein R.sub.1 is hydrogen, alkyl or alkenyl of up to 10 carbon atoms,A is a --CH.sub.2 CH.sub.2 --, trans--CH.dbd.CH--, or --C.tbd.C-- group,W is a free or functionally modified hydroxymethylene group or a free or functionally modified ##STR2## wherein the OH-group can be in the .alpha.- or .beta.-position,D is ##STR3## alkylene, or unsaturated alkylene each of which can optionally be substituted by fluorine atoms,m is 1, 2 or 3,E is a direct bond, a --C.tbd.C-- group, or --CR.sub.4 .dbd.CR.sub.5 -- group, wherein R.sub.4 is hydrogen or an alkyl group of 1-5 carbon atoms, and R.sub.5 is hydrogen or an alkyl group of 1-5 carbon atoms, and R.sub.5 is hydrogen, halogen, or an alkyl group of 1-5 carbon atoms,R.sub.2 is alkyl or alkenyl of up to 10 carbon atoms, cycloalkyl of 3-10 carbon atoms or an optionally substituted aryl group of 6-10 carbon atoms, or a heterocyclic group, andR.sub.

Abstract: An anti-fungal complex formed of a polyene anti-fungal agent, such as amphotericin B, and cyclodextrin, preferably .gamma.-cyclodextrin, is provided. The complex which includes amphoterin B has improved water solutility and stability over prior art amphotericin B anti-fungal agents. A method for forming the complex is also provided wherein anti-fungal agent, such as amphoterin B, is dissolved in an aqueous solution of cyclodextrin of pH ranging from about 9 to about 12 and the resulting solution is maintained at a pH ranging from about 6 to about 8 to form the subject complex. The solution can be lyophilized as desired to achieve higher solubility.

Abstract: Mixtures containing cyclodextrins are fractionated by affinity chromatography on matrices bearing hydrophobic ligands. The size and structure of the hydrophobic ligands can be altered to change the relative affinity of the ligands for different cyclodextrins and thus influence chromatographic fractionation.

Abstract: Compounds of the general formula (1) ##STR1## in which n is 1 or 2;m is 2-5 and X is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; or m is 1-4 and X is --CH.dbd.C.dbd.CH--;R.sup.1 is phenyl, substituted phenyl or naphthyl;Y is substituted or unsubstituted 3-phenoxy-2-hydroxypropyl.These compounds inhibit gastric acid secretion and provide gastrointestinal cytoprotection, and may be formulated for use in the treatment of ulcers.

Abstract: Compounds are described of formula ##STR1## wherein n is 1 or 2;m is 2-5 and X is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; or m is 1-4 and x is --CH.dbd.C.dbd.CH--;Z is --CH.sub.2 OH, --CHO or --CONHR.sup.1 [where R.sup.1 is a hydrogen atom or C.sub.1-4 alkyl, aryl, --COR.sup.2 (where R.sup.2 is a hydrogen atom or a C.sub.1-4 alkyl or aryl group) or --SO.sub.2 R.sup.3 (where R.sup.3 is a C.sub.1-4 alkyl or aryl group)];Y is substituted or unsubstituted 3-phenoxy-2-hydroxypropyl.These compounds inhibit gastric acid secretion and provide gastrointestinal cytoprotection, and may be formulated for use in the treatment of ulcers.

Abstract: Compounds are described of formula (1) ##STR1## wherein m is 1 to 4;n is zero, 1 or 2;p is 1 to 4;Z is a group CO.sub.2 R.sup.1 where R.sup.1 is(a) a hydrogen atom or an alkyl, phenalkyl or 2-naphthyl group;(b) phenyl or substituted phenyl;(c) --CH.sub.2 COR.sup.5 where R.sup.5 is phenyl substituted phenyl or 2-naphthyl;or Z is --CH.sub.2 OH, --CHO or CONHR.sup.9 [where R.sup.9 is a hydrogen atom or alkyl, aryl, --COR.sup.10 (where R.sup.10 is a hydrogen atom or an alkyl or aryl group) Or --SO.sub.2 R.sup.11 (where R.sup.11 is an alkyl or aryl group)];Y is substituted or unsubstituted 3-phenoxy-2-hydroxypropyl.These compounds inhibit gastric acid secretion and provide gastrointestinal cytoprotection, and may be formulated for use in the treatment of ulcers.

Abstract: Branched dextrin and linear oligosaccharides are produced by degrading starch with alpha-amylase followed by fractionating with a gel-type filtering agent. The branched dextrin is useful in the food fabrication.

Abstract: The invention is concerned with dihydrobenzothiophene and thiochromane derivatives of the generic formula ##STR1## The compounds show anti-hypertensive, platelet aggregation inhibiting, hypolipemic, antianoxic spasmolytic, anthithrombotic, calcium antagonizing and neuroleptic activity.

Abstract: Low molecular weight chymotrypsin analogs exhibiting the binding and catalytic groups of the real enzyme of the formula ##STR1## where D equals .alpha.-, .beta.- or .gamma.-cyclodextrin; P is X or (CH.sub.2).sub.n X, wherein n equals 0 to 2 and X equals S, NH, or 0; Q equals substituted phenyl with the carboxylate ion attached to the ortho position or equals (CH.sub.2).sub.n, wherein n equals 0 to 3; and R equals hydrogen --CH.sub.3 or --C.sub.2 H.sub.5.The enzyme models are useful as an analytical model mimicking the real enzyme, a stain remover, a laundry detergent additive, a food additive, and as a therapeutic agent for treating enzyme deficiencies.

Abstract: A bath preparations comprise a cyclodextrin clathrate compound of a component of milk. The bath preparations may further comprise egg white and/or at least one vitamin selected from the goup consisting of vitamin A, vitamins B, vitamin C, Vitamin D, vitamin E, vitamin F and vitamin P. The bath preparations may be used together with a saccharifying enzyme, which is mixed with the bath preparations or which is insulated from the bath preparations.A method for producing the bath preparations comprises contacting milk, which is selected from the group consisting of cow's milk, components of cow's milk, powdered milk, evaporated milk, components of evaporated milk, raw cream and components of raw cream, with cyclodextrin to form a cyclodextrin clathrate compound of the component of milk, and mixing the cyclodextrin clathrate compound of the component of milk with other raw materials of baths.

Abstract: Cycloartenol ferulate/cyclodextrin complex is prepared by including cycloartenol ferulate, which is a component of .gamma.-oryzanol and hardly soluble in water, with cyclodextrin to thereby elevate its solubility in water and improve its absorption through digestive tracts. Thus various pharmaceutical and physiological effects of cycloartenol ferulate are further improved.

Abstract: Prostaglandin analogues of the formula: ##STR1## (wherein R.sup.1 represents a hydrogen atom or an aliphatic or alicyclic hydrocarbon radical, Y.sup.1 represents a carbonyl or hydroxymethylene group, A.sup.1 represents an alkylene linkage containing 1, 2 or 3 carbon atoms and optionally bearing a methyl or ethyl substituent, R.sup.2 represents a hydrogen atom or a methyl or ethyl group and R.sup.3 represents a hydrogen atom or R.sup.2 and R.sup.3 form an alkylene linkage containing 2 or 3 carbon atoms, optionally bearing a methyl or ethyl substituent, such that the symbols A.sup.1, R.sup.2 and R.sup.3, together with the carbon atoms through which they are connected, may form a cycloalkyl ring of 5, 6, 7 or 8 carbon atoms, optionally bearing one or two methyl or ethyl substituents, or A.sup.1 and R.sup.

Abstract: A crosslinking agent constituted by a cyclodextrin clathrate compound of a compound having isocyanate group(s). This crosslinking agent is stable at room temperature and very readily initiates crosslinking. The crosslinking agent is prepared by reacting a compound having isocyanate group(s) with cyclodextrin at 65.degree. C. or below in water, and recovering the clathrate compound from the water.

Abstract: A new and improved herbicidal and plant growth regulating composition, and the method of manufacturing that composition. The new complex composition of the invention is an inclusion complex of one more benzene sulphonyl urea derivative of the general formula (II) ##STR1## and two or more moles of beta cyclodextrine of the formula (I).

Abstract: The novel water-soluble compounds are the ethyl ether and the N,N-dialkyl(C.sub.1 to C.sub.4)aminoethyl ethers of .beta.-cyclodextrin (.beta.-CD).The process for the preparation of these ethers is performed by reacting .beta.-CD with an etherifying agent in a basic liquid reaction medium. The reaction medium contains an alkali-metal hydroxide, water and at least one water-miscible organic solvent (for example, dimethoxyethane or isopropanol).

Abstract: Disclosed herein is an oral mobenzoxamine preparation which comprises a clathrate compound of mobenzoxamine or a salt thereof and cyclodextrin. Since the clathrate compound remains extremely stable even when stored for a long period of time and its absorption through the digestive tract is good upon its oral administration, the clathrate compound can be used advantageously as an orally-dosable preparation.

Abstract: New inclusion compounds of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dio xide with .alpha., .beta. or .gamma. cyclodextrins, obtained by reaction of said cyclodextrins and said 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dio xide in aqueous or water/organic solutions are described. The ratio between 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-1,1-dioxide and the cyclodextrins is comprised between 1:10 and 1:1; preferably, it is about 1:2.5.The compounds of the invention possess high antiinflammatory and analgesic activities, together with a considerably reduced gastrolesive action.

Abstract: 2,6-di-O-methyl-beta-cyclodextrin complexes of compounds of the formula (1a) ##STR1## wherein R.sup.2' stands for C.sub.1 to C.sub.12 alkyl or a group of the formula ##STR2## in which R.sup.11 is C.sub.1 to C.sub.4 alkyl;R.sup.12 is hydrogen or C.sub.1 to C.sub.4 alkyl;n is 0 or 1;p is 1 to 4;r is 1 to 4; andR.sup.3' and R.sup.4' are each C.sub.1 to C.sub.4 alkyl, or pharmaceutically salts thereof are disclosed, having analgesic activity.

Abstract: An inclusion compound composed of tripamide and cyclodextrin markedly improves the solubility of tripamide which is effective for treatment of essential hypertension.

Abstract: An occlusion compound of 2-nitroxymethyl-6-chloropyridine with .beta.-cyclodextrin is disclosed herein as well as a process for preparing the occlusion compound thereof. The occlusion compound of the present invention has a molar ratio of 2-nitroxymethyl-6-chloropyridine to .beta.-cyclodextrin of between about 1:1 and about 3:1. The present occlusion compound is nonvolatile, thereby overcoming the problems associated with the volatility of the 2-nitroxymethyl-6-chloropyridine for pharmacuetical preparations. The process of the present invention is carried out by reacting 2-nitroxymethyl-6-chloropyridine with .beta.-cyclodextrin either by kneading both compounds together with a small amount of a solvent or by mixing both compounds in an appropriate solvent, such as water. The occlusion compound is then precipitated, separated and further purified by conventional methods.

Abstract: The invention relates to a new medicinal composition containing .alpha.-[3-chloro-4-(3-pyrrolin-1-yl)-phenyl]-propionic acid as the pharmacologically active ingredient, having analgesic and antiinflammatory properties, which composition has markedly improved properties, particularly with respect to taste and stability.

Abstract: A novel prostaglandin analogue of the formula: ##STR1## [wherein the symbol represents .beta.-configuration, the dotted line ---------- represents .alpha.-configuration, and the double bond between C.sub.13 -C.sub.14 represents transconfiguration] and cyclodextrin clathrates thereof, and non-toxic salts thereof are useful for the treatment and/or prevention of diseases induced by platelet aggregation, such as thrombosis, or induced by cytodamage.

Abstract: An inclusion complex is disclosed of N-(1-phenylethyl)-3, 3-diphenyl-propylamine or its hydrochloride complexed with a cyclodextrin as well as a process for the preparation thereof and pharmaceutical compositions containing same. The new inclusion complexes have coronary dilatory activity and have greater water soluble than simple N-(1-phenylethyl)-3, 3-diphenyl-propyl amine or the hydrochloride thereof.

Abstract: Prostaglandin analogues of the general formula: ##STR1## (wherein R.sup.1 represents a hydrogen atom or a straight- or branched-chain alkyl group, Y.sup.1 represents a carbonyl or hydroxymethylene group, represents a single or double bond, A.sup.1 represents an alkylene linkage containing 2 or 3 carbon atoms and optionally bearing a methyl or ethyl substituent, R.sup.2 represents a hydrogen atom or a methyl or ethyl group and R.sup.3 represents a hydrogen atom or else R.sup.2 and R.sup.3 form an alkylene linkage containing 2 or 3 carbon atoms, optionally bearing a methyl or ethyl substituent, such that the symbols A.sup.1, R.sup.2 and R.sup.3, together with the carbon atoms through which they are connected, form a cycloalkyl ring of 6, 7 or 8 carbon atoms, optionally bearing one or two methyl or ethyl substituents, X.sup.1 represents an ethylene or trans-vinylene group, Y.sup.2 represents a carbonyl or hydroxymethylene group, and either (i) A.sup.

Abstract: Metal-containing or metal-free phthalocyanine-polysaccharide complex defined below is used for removal of mutagens and carcinogens present in aqueous solutions, the said complex having formula of ##STR1## wherein Pc is a metal-containing or metal-free phthalocyanine residue, A is an alkylene group having 2 to 6 carbon atoms or an arylene group having 1 to 3 rings, the integers m and n satisfy both 2<m+n.ltoreq.4 and 1.ltoreq.n.ltoreq.2, and Z is an activated polysaccharide residue.

Abstract: This invention relates to inclusion compounds of cyclodextrin with the compounds of the general formula [I] and salts thereof, which show pharmacological effects (for example antihypertensive effect), ##STR1## wherein A is straight or branched lower alkylene;R.sup.1 is hydrogen or lower alkyl;R.sup.2 is hydrogen, lower alkyl, phenyl, phenyl-lower alkyl, hydroxyphenyl-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, guanidino-lower alkyl, imidazolyl-lower alkyl, indolyl-lower alkyl, mercapto-lower alkyl or lower alkylthio-lower alkyl;R.sup.1 or R.sup.2 may join to complete pyrrolidine ring or thiazolidine ring, and each ring may be substituted by phenyl or pyridyl, and phenyl may be resubstituted by hydroxy, lower alkoxy, halogen, nitro or sulfamoyl;R.sup.3 is hydrogen or ##STR2## said lower alkyl and lower alkoxy having 1 to 6 carbon atoms.

Abstract: Prostaglandin I.sub.2 analogues of the formula: ##STR1## [wherein the symbol between the carbon atoms in positions 5 and 6 represents a single or double bond, Y represents ethylene or trans-vinylene, R.sup.1 represents hydrogen, alkyl of 1 to 12 carbon atoms, aralkyl of 7 to 12 carbon atoms, cycloalkyl of 4 to 7 carbon atoms optionally substituted by alkyl of 1 to 4 carbon atoms, phenyl optionally substituted by chlorine, trifluoromethyl, alkyl of 1 to 4 carbon atoms or phenyl, a --C.sub.m H.sub.2m COOR.sup.7 group (wherein m represents an integer of from 1 to 12 and R.sup.7 represents alkyl of 1 to 4 carbon atoms), a --C.sub.n H.sub.2n OR.sup.8 group (wherein n represents an integer of from 2 to 12 and R.sup.8 represents hydrogen or alkyl of 1 to 4 carbon atoms) or a ##STR2## group (wherein R.sup.9 and R.sup.10 each represent alkyl of 1 to 4 carbon atoms and n is as hereinbefore defined), R.sup.2 represents hydrogen or a hydroxy-protecting group, R.sup.

Abstract: A complex of an acid addition salt of (2'-benzyloxycarbonyl)phenyl trans-4-guanidinomethylcyclohexanecarboxylate and a cyclodextrin. The complex is useful for the treatment of ulcers.

Abstract: Prostaglandin E.sub.1 analogues of the general formula: ##STR1## (wherein R.sup.1 represents a single bond or a straight- or branched-chain alkylene group of from 1 to 5 carbon atom(s), R.sup.2 represents a cycloalkyl group of from 4 to 7 carbon atoms either unsubstituted or substituted by at least one straight- or branched-chain alkyl group of from 1 to 8 carbon(s), and the double bond between C.sub.13 and C.sub.14 is trans) and cyclodextrin clathrate thereof, are useful in the prevention or treatment of cytodamage associated with digestive system disease, especially liver damage.

Abstract: A photocurable, ethylenically-unsaturated, water-soluble oligomer comprising the reaction product of 100 parts by weight of a dextrin compound, and 35 to 70 parts by weight of at least one ethylenically-unsaturated monomer capable of reacting with at least one hydroxyl group of the dextrin compound, the oligomer having an average in the range of 0.1 to 0.7 ethylenically-unsaturated moiety per anhydroglucose unit and an equivalent weight of 440 to 990, and at least 75 weight percent of the oligomer is water soluble at 20.degree. C. in a concentration of at least 2.5 percent by weight. The oligomer when photocured in combination with an ethylenically-unsaturated monomer is useful as a photoresist in positive-acting, water-developable, lithographic printing plates.

Abstract: Highly dielectric organic compounds can be obtained by cyanoethylating a dihydroxyalkylate of a water-soluble polysaccharide or a derivative thereof with acrylonitrile.

Abstract: Cardiac contractility agents are provided which are 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamin e cyclodextrin complexes.

Abstract: Cardiac contractility agents are provided which are 3,4-di-isobutyryloxy-N-?3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta- phenethylamine, preferably orally deliverable forms which are cyclodextrin complexes.

Abstract: An inclusion compound of p-hexadecylamino benzoic acid sodium salt in .beta.-cyclodextrin which provides enhanced bioavailability of this antiatherosclerotic agent.

Abstract: New indoxylmaltodextrins, an enzymatic process for their preparation and their use as a substrate for the analytical detection and the determination of amylases, and rapid diagnostic agents which contain such indoxylmaltodextrins are described.

Abstract: Moranolines are produced which are useful for controlling blood sugar levels.

Abstract: A water-insoluble immunological reagent being formed from discrete particles of a latex carrier to which a water-soluble polyhydroxy compound is covalently bound having condensed thereto through a covalent link an immunologically active material; process for the manufacture of said reagent; a kit containing said reagent and the use of said reagent in immunological determinations.

Abstract: Prostaglandin I.sub.2 analogues of the formula: ##STR1## [wherein Y represents ethylene or trans-vinylene, R.sup.1 represents hydrogen, alkyl of 1 to 12 carbon atoms, aralkyl of 7 to 12 carbon atoms, cycloalkyl of 4 to 7 carbon atoms optionally substituted by at least one alkyl group containing from 1 to 4 carbon atoms, phenyl unsubstituted or substituted by at least one chlorine atom, trifluoromethyl group, alkyl group containing from 1 to 4 carbon atoms or phenyl group, a --C.sub.m H.sub.2m COOR.sup.4 group (wherein m is an integer from 1 to 12 and R.sup.4 represents alkyl of 1 to 4 carbon atoms), a C.sub.n H.sub.2n OR.sup.5 group (wherein n is an integer from 2 to 12 and R.sup.5 represents hydrogen or alkyl of 1 to 4 carbon atoms), or a ##STR2## (wherein n is as hereinbefore defined and R.sup.6 and R.sup.7 each represent alkyl of 1 to 4 carbon atoms), R.sup.2 represents hydrogen, methyl or ethyl, X represents a --C.sub.p H.sub.2p --group (wherein p is an integer from 2 to 8) or a ##STR3## (wherein R.sup.

Abstract: Prostaglandin analogues of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents hydrogen or alkyl of 1 through 12 carbon atoms, R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, or alkyl of 1 through 12 carbon atoms or an aryl group, with the proviso that at least one of the symbols R.sup.1, R.sup.2 and R.sup.3 represents an alkyl or aryl group, are new compounds possessing useful pharmacological properties; they are especially useful for the treatment of gastric ulceration.

Abstract: Nucleosides of the formula ##STR1## wherein Z is a free or blocked polysaccharide residue;X is O or S;m is 0 or 1;M.sub.1 is 0 or 1;R.sub.1 and R.sub.2 collectively are a saturated or unsaturated, optionally substituted bivalent organic radical containing up to two nitrogen atoms; andR.sub.3 and R.sub.4 independently are hydrogen, alkyl, alkoxycarbonyl, alkylaminocarbonyl, carboxyl, or nitrile group, or collectively are one of the bivalent radicals ##STR2## and substituted or hydrogenated analogs thereof, are sorbents useful for the separation of nucleoside mixtures.

Abstract: Nitroglycerine inclusion compound in cyclodextrin is obtained by contacting cyclodextrin with nitroglycerine in the presence of water. The inclusion compound is very stable as a quick effective drug for treating angina pectoris and easy in handling.

Abstract: Malto-dextrin poly(H-)sulfate and salts thereof useful as inhibitors of the complement system.

Abstract: A compound of the formula: ##SPC1##Wherein R.sup.2 is mesitylsulfonyl or 2,4,6-triisopropylbenzenesulfonyl and n is an integer of 6 or 7, is reacted with a compound of the formula:R.sup.3 --Hwherein R.sup.3 is amino, methyamino, dimethylamino or azido. When R.sup.3 is azido group, the product thus obtained is further subjected to catalytic hydrogenation. A cyclodextrin derivative of the formula: ##SPC2##Wherein R.sup.1 is amino, methylamino or dimethylamino and n is the same as defined above, is obtained. Said cyclodextrin derivative is useful as a hypolipemic agent.